Johnson & Johnson has reported late‑breaking phase 2 results showing that nipocalimab met the primary endpoint of reducing ...

Deep Science Ventures (DSV) and Medicines Discovery Catapult (MDC) have formed a strategic partnership to tackle one of ...

JJP Biologics has reported positive interim findings from its ongoing phase 1b study of nebaprubart (JJP‑1212) in patients with linear IgA disease, a rare autoantibody‑driven blistering disorder with ...

Aragen has completed the technology transfer and first commercial-scale GMP manufacturing runs for Renaissance Pharma’s lead ...

Resolution Therapeutics has welcomed new four‑year follow‑up data from the University of Edinburgh’s MATCH trial, which ...

Pierre Fabre Laboratories has received a positive opinion from the European Medicines Agency’s CHMP recommending approval of ...

This issue reminds us that humankind remains the enduring question, and diversity in clinical trials is the answer (even if ...

Compressed air is among the largest energy expenses in pharmaceutical manufacturing and must remain entirely contamination-free.

Partnership to develop next‑generation T‑cell engagers for solid tumours Oxford BioTherapeutics has entered a multi‑year collaboration with Bristol Myers Squibb to discover and develop novel T‑cell ...

Nihr‑funded phase 2 study to assess progesterone delivery using Callavid device Calla Lily Clinical Care has dosed the first patients in its Freedom clinical trial, a nihr‑funded study evaluating the ...

CatalYm has dosed the first patient in its global GDFATHER-HCC-01 study, a phase 2b trial evaluating visugromab in combination with chemoimmunotherapy for people with unresectable or metastatic ...